Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.68 | -2.42008307748 | 110.74 | 113.8 | 104.86 | 2939 | 107.93197577 | DE |
| 4 | -5.08 | -4.49001237405 | 113.14 | 117.84 | 104.86 | 1860 | 111.20575929 | DE |
| 12 | -13.8 | -11.3244707041 | 121.86 | 122.9 | 104.86 | 1776 | 113.93552682 | DE |
| 26 | 2.68 | 2.54317707345 | 105.38 | 132.16 | 99.86 | 2394 | 116.89630575 | DE |
| 52 | 13.51 | 14.2887361185 | 94.55 | 132.16 | 90.01 | 2362 | 108.33614445 | DE |
| 156 | 35.44 | 48.8019829248 | 72.62 | 132.16 | 57.18 | 3814 | 83.8766944 | DE |
| 260 | 52.05 | 92.9298339582 | 56.01 | 132.16 | 52.06 | 4076 | 76.2748588 | DE |
wadegarret
5分前
Kjv
5分前
Guido2
5分前
Smartypants2
6分前
PennyRookie0
6分前
PEACHMAN
6分前
my3sons87
6分前
uranium-pinto-beans
7分前
uranium-pinto-beans
7分前
jrf30
8分前
Tahoe2468
8分前
chen1992
8分前
PRmaniac
9分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。